CTOs on the Move

Prometheus Biosciences

www.prometheusbiosciences.com

 
Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Olivier Laurent
Chief Technology Officer Profile

Funding

Prometheus Biosciences raised $130M on 11/09/2020
Prometheus Biosciences raised $218.5M on 03/16/2021

Similar Companies

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

Cima Labs

CIMA Labs Inc. develops and manufactures orally disintegrating tablet and enhanced-absorption oral drug delivery systems. The Company's lead, orally disintegrating tablet technologies, OraSolv and DuraSolv, allow an active drug ingredient, which is

Bioforward

Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanford Jackson Medical Center

Sanford Jackson Medical Center is a Jackson, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.